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Abstract: Prominent eyelashes are generally recognized as enhancing beauty and are often 
desired by women. Until recently, the options available to augment the prominence of eyelashes 
were limited to makeup, over-the-counter products, artificial eyelashes, and eyelash transplanta-
tion. Originally approved for the treatment of ocular hypertension, the prostamide, bimatoprost, 
is now approved for the treatment of hypotrichosis of the eyelashes. Bimatoprost ophthalmic 
solution 0.03%, applied once daily to the skin of the upper eyelid margin using sterile single-
use-per-eye applicators, increases eyelash growth, including length, thickness, and darkness. 
The effectiveness of bimatoprost for eyelash growth has been demonstrated by clinician ratings, 
digital image analysis, and patient-reported measures of satisfaction. The effects of bimatoprost 
treatment on eyelash length, thickness, and darkness are believed to result from longer anagen 
duration, increased hair bulb thickness, and increased melanogenesis, respectively. Dermally 
applied bimatoprost appears to be associated with a lower incidence of adverse events than 
administration of the medication as an eyedrop. This more favorable safety and tolerability 
profile is likely mediated by decreased exposure of ocular tissues to bimatoprost when applied 
dermally. Taken together, available data suggest that cutaneous application of bimatoprost 
ophthalmic solution 0.03% safely and effectively enhances upper eyelash growth.
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Introduction
Although the ideals of physical beauty vary over time and by culture, general consen-
sus supports the integral role of the eyes in defining beauty.1 The practice of taking 
steps to enhance the appearance of the eyes, specifically the eyelids and eyelashes, 
dates back thousands of years.2 Mulhern et al showed that enhancing the appearance 
of women’s eyes (using eyeliner, eye shadow, and mascara) significantly increased 
attractiveness as rated by both male and female observers.3 With respect to women’s 
eyelashes, most cultures highly value long thick lashes, and an increase in eyelash 
growth is thought to confer a positive psychologic effect.4–6
Several options exist for women looking to enhance the appearance of their 
  eyelashes. Some agents, such as mascara and artificial eyelashes, have been available 
for decades. Only recently, however, has the US Food and Drug Administration (FDA) 
approved a product, bimatoprost ophthalmic solution 0.03% (Latisse®; Allergan, 
Inc., Irvine, CA), for the treatment of hypotrichosis of the eyelashes. This product 
has demonstrated an increase in the growth of eyelashes, including length, thickness, 
and darkness.7 This article will review the currently available options to improve the 
appearance of eyelashes, with a focus on the recently approved prescription drug, Clinical, Cosmetic and Investigational Dermatology 2010:3 40
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bimatoprost ophthalmic solution 0.03%. To better understand 
the mechanisms of action by which bimatoprost ophthalmic 
solution 0.03% is believed to influence eyelash growth, we 
will also review the physiology of normal eyelash growth. 
Finally, the clinical data on the efficacy of bimatoprost for 
eyelash growth and the agent’s safety data, both as treatment 
for hypotrichosis (applied dermally) and ocular hypertension 
(instilled ocularly), will be discussed.
Eyelash physiology
Physiologically, eyelashes serve a protective function and, as 
with all hairs on the body, are generated by the continuous 
cycling of hair follicles. They prevent debris from entering 
the eye and are responsible for triggering the blink reflex 
when touched.8–10 Similar to other hair follicles on the body, 
eyelash follicles are connected to sebaceous glands (ie, glands 
of Zeis).9,10 Unlike other follicles, however, the follicles of 
eyelashes are not associated with arrectores pilorum.11 The 
number of follicles cannot be increased after birth because 
all follicles develop during embryogenesis.12 Individuals 
can experience the loss of previously normal eyelashes, 
which may or may not be accompanied by the destruction 
of their respective hair follicles. This condition, madrosis 
(also referred to as milphosis), can have numerous causes, 
including alopecia areata, infection (eg, leprosy), endocrine 
disease (eg, hypothyroidism), medications (eg, antimetabo-
lites), radiation, or trauma.10
As a result of their length, medullation, and dark pigmenta-
tion, eyelashes are properly classified as terminal hairs, in con-
trast with vellus or intermediate hairs.11 In fact, they represent 
the thickest hairs on the body.11 Additionally, eyelashes are 
often darker than scalp hair and generally retain their pig-
mentation with age, making it unusual for them to turn grey.9,11 
Upper eyelashes are typically arranged in two or three rows and 
total approximately 100 to 150 lashes per eye.9,10 Lower lashes 
are shorter and fewer in number than upper eyelashes.9,13,14
To understand the mechanisms of action underlying 
normal eyelash growth, it is important to review the current 
information on the eyelash hair cycle (Figure 1, data on file; 
Allergan, Inc.).7,11,14,15 Whereas the cycle of scalp hair has 
been extensively studied, few studies have been conducted 
on eyelashes. Traditionally thought to last approximately 
five to 12 months,11,14,15 new data suggest that the duration 
of the entire cycle may be shorter.13 The hair cycle can be 
divided into three main phases: anagen, catagen, and telogen. 
Anagen, the growth phase, is a time of rapid cell proliferation 
and differentiation and its duration, approximately one to two 
months, largely determines the length of eyelashes.8,11,13–16 
Melanogenesis, and the subsequent transfer of pigment from 
melanocytes to medullary and cortical cells of the follicle, 
occurs only during anagen.11 Eyelashes grow at a rate of 
approximately 0.12 to 0.15 mm/day.13,15 This growth rate can 
be contrasted with the 0.3 to 0.4 mm/day observed in the much 
longer anagen phase (up to eight years) of scalp hair.11,12,17,18
During catagen, the transition phase of the hair cycle, 
epithelial elements of the follicle (keratinocytes) undergo 
programmed cell death (ie, apoptosis).18 Eyelash follicles are 
believed to remain in catagen for approximately 15 days.11 
Following catagen, eyelashes enter telogen, the resting phase 
of the hair cycle. During telogen, the follicle remains dormant, 
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cycle11,14,15 
Telogen 
normally ≈ 4–9 months
Exogen 
Hair falls out
Catagen 
normally ≈15 days
Anagen 
prolongs anagen 
(Data on file, Allergan, Inc.) 
increases percentage of 
eyelashes in anagen7
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Bimatoprost Ophthalmic 
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Figure 1 Hair cycle of normal eyelashes (left) and potential mechanisms of action of bimatoprost ophthalmic solution 0.03% on the eyelash cycle (right) (data on file, 
Allergan, Inc.).7,11,14,15Clinical, Cosmetic and Investigational Dermatology 2010:3 41
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not exhibiting significant cell differentiation, proliferation, or 
apoptosis.16 The telogen phase of eyelash follicles has been 
reported to last from 100 days to nine months.11,14,15 The active 
shedding of an old eyelash occurs during the transition from 
telogen to anagen in a process known as exogen.8,16,17
Human hair growth is asynchronous, indicating that, at any 
given time, some follicles are undergoing anagen while others 
are in the catagen or telogen phase.11,12 Therefore, the propor-
tion of follicles in one phase of the hair cycle is indicative of 
the relative duration of that phase. While approximately 41% 
of upper eyelid eyelash follicles are active at any given time, 
84% of scalp follicles meet the same criteria.11,14 Conversely, 
approximately half of all eyelash follicles are in telogen com-
pared with 5% to 15% of scalp follicles.11,12,14,17 In summary, 
relative to scalp hair, eyelashes have a much shorter anagen 
phase and a relatively longer telogen phase.
Bimatoprost ophthalmic 
solution 0.03%
Bimatoprost ophthalmic solution 0.03% (Lumigan®; Allergan, 
Inc.) was initially developed as an ocular antihypertensive and, 
in 2001, was approved for the reduction of elevated intraocular 
pressure (IOP) in patients with open-angle glaucoma or 
ocular hypertension.19 As a glaucoma treatment, bimatoprost 
ophthalmic solution 0.03% is administered as a drop into the 
affected eye once daily. It is thought to lower IOP by increas-
ing aqueous humor outflow through the trabecular meshwork 
and uveoscleral pathways.19–23 The safety and effectiveness of 
bimatoprost ophthalmic solution 0.03% for the treatment of 
increased IOP has been demonstrated in numerous short- and 
long-term (up to four years) clinical trials.24–28 Data suggest 
that, presently, prostaglandin analogs such as bimatoprost 
ophthalmic solution 0.03% are the most efficacious antiglau-
coma drugs available.20,29 A synthetic analog of prostaglandin 
F2α-ethanolamide or prostamide F2α, bimatoprost is known to 
bind to the prostamide receptor, a pharmacologically distinct 
receptor from prostanoid FP receptors, which are known to 
bind prostaglandin analogs.20,29
The recognition that bimatoprost ophthalmic solution 
0.03% is capable of influencing eyelash growth was a seren-
dipitous discovery based on observations of patients receiv-
ing the drug in trials that assessed the drug’s antihypertensive 
properties.30 In these trials, patients commonly reported 
eyelash changes, which were classified as adverse events. 
For instance, in a pair of one-year, multicenter, random-
ized, double-masked, parallel-group, active-controlled trials, 
42.6% of patients treated with once-daily bimatoprost (one 
drop instilled into each eye) experienced eyelash growth.28 
Since eyelash properties were not specifically examined in 
the trials, such reports may have failed to capture the true 
incidence of these effects.
Prostaglandin analogs including latanoprost and travo-
prost, both used to treat glaucoma, have also been associ-
ated with eyelash changes when instilled ocularly.6,11,31 In a 
three-month head-to-head trial designed to directly compare 
the safety and efficacy of bimatoprost ophthalmic solution 
0.03% and latanoprost in patients with glaucoma and ocular 
hypertension, the incidence of the side effect of increased 
eyelash growth was significantly higher in patients treated 
with once-daily bimatoprost than in those treated with once-
daily latanoprost.32 Whether such differences exist when the 
agents are applied cutaneously (ie, to the dermal margin of 
the eyelid) has not yet been studied. Despite proven effective-
ness for the treatment of glaucoma, the safety and efficacy of 
dermal application of latanoprost, travoprost, and unoprostone 
for the purposes of eyelash growth have not been evaluated in 
controlled clinical trials. Furthermore, the use of these medi-
cations for aesthetic purposes is not approved by the FDA; 
therefore, they are not discussed in this manuscript.
Although the precise mechanisms by which bimatoprost 
ophthalmic solution 0.03% increases eyelash growth have not 
been fully elucidated, it is believed to alter the eyelash hair 
cycle as depicted in Figure 1 (data on file, Allergan Inc.).7,11,14,15 
Studies conducted in mice suggest that treatment with bima-
toprost results in an increased proportion of follicles being 
in anagen, accompanied by a simultaneous decrease in the 
proportion of hair follicles in telogen (data on file, Allergan, 
Inc.). These findings suggest that bimatoprost ophthalmic 
solution 0.03% stimulates the transition from telogen to 
anagen and prolongs the duration of anagen, thereby con-
tributing to the increased length of eyelashes. Animal studies 
also demonstrate that treatment with bimatoprost ophthalmic 
solution 0.03% results in increased dermal papilla and hair 
bulb diameters among follicles undergoing early anagen. 
The findings are consistent with the bimatoprost-associated 
increased eyelash thickness also observed in mice. Increased 
eyelash darkness putatively results from increased melanin 
production. Bimatoprost-induced increases in melanogenesis 
do not appear to be associated with inflammatory reactions, 
melanocyte proliferation, or melanocyte atypia.33 Treatment 
with bimatoprost ophthalmic solution 0.03% does not increase 
the original number of eyelash follicles (data on file, Allergan, 
Inc.). Still, it is possible that bimatoprost ophthalmic solution 
0.03% appears to increase the number of visible hairs as a 
result of the increased speed at which eyelashes are replaced 
(due to the stimulation of follicles from telogen to anagen) Clinical, Cosmetic and Investigational Dermatology 2010:3 42
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and the increased time lashes remain in the follicle (due to 
the prolongation of anagen and subsequent delay of exogen). 
Additionally, while the number of follicles remains constant, 
the types of hair they produce can change, such that bimato-
prost may cause (previously) undetectable or less visible vellus 
hairs to become pigmented thicker terminal hairs.19,34
Nonbimatoprost options for eyelash 
enhancement
Prior to reviewing the results from the recent pivotal trial 
evaluating the efficacy and safety of bimatoprost ophthalmic 
solution 0.03% for eyelash growth, it is important to note 
that women have several options available to enhance the 
appearance of their eyelashes. Mascara, the oldest and most 
commonly used option today, contains a mixture of waxes 
and pigments in addition to resins or petroleum distillates.2,35 
It aims to temporarily darken, lengthen, and thicken eye-
lashes. Mascaras come in a variety of colors, formulations, 
and costs, and are generally accompanied by various applica-
tors (ie, brushes). The effects are temporary and subject to 
smudging. Although mascara contains preservatives, a risk 
of microbial contamination and infection remains.2 Mascara 
can also cause irritation and contact dermatitis, as well as 
conjunctival pigmentation.2,35
Several nonmascara over-the-counter products are 
advertised to increase the length, fullness, and/or darkness 
of eyelashes. These products are sometimes marketed as 
“eyelash stimulators”,36 “eyelash enhancement serums”,37 or 
“eyelash conditioners”,38–40 and contain various ingredients 
such as “proprietary peptides”,40 natural extracts,41 vitamins,40 
and prostaglandin analogs.42 Since cosmetic products do not 
require FDA approval, they have not been critically evalu-
ated for efficacy nor has their short- or long-term safety been 
fully studied.
Artificial eyelashes, made from human hairs or strands 
of synthetic fibers, have been used by women to enhance 
the appearance of their eyelashes for quite some time. These 
lashes can be applied as a strip onto the eyelid or attached 
individually to existing eyelashes.35,43 When applied to indi-
vidual eyelashes, the procedure can be lengthy and costly.43 
Artificial eyelashes are commonly secured using glues con-
taining methacrylate, which can cause allergic reactions in 
susceptible patients.35 The artificial eyelashes can remain in 
place from several days to several weeks, depending on the 
product used.35,43
Originally developed as a means of eyelash reconstruc-
tion, eyelash transplants involve the transfer of scalp follicles 
onto the eyelid.44 Although controversial, the procedure is 
also being used for aesthetic augmentation of eyelashes.44,45 
Because the lashes are actually scalp hair, patients must 
regularly trim and curl the implanted lashes. The risks of 
eyelash transplantation include postoperative pain, bleed-
ing and hematoma, scar formation, altered sensation, eyelid 
ptosis, dry eye, and blindness.44
Efficacy of bimatoprost ophthalmic 
solution 0.03% for eyelash growth
When prescribed for the treatment of eyelash hypotri-
chosis, bimatoprost ophthalmic solution 0.03% is to be 
applied daily to the skin of the upper eyelid margin at 
the base of the eyelashes using the accompanying sterile 
single-use-per-eye applicators.7 Patients should be advised to 
apply the medication after washing their face and removing 
all makeup. Contact lens wearers should remove their lenses 
prior to application and should not reinsert them for at least 
15 minutes following application. Excess solution beyond 
the eyelid should be absorbed with a cloth or tissue.
The efficacy of bimatoprost ophthalmic solution 0.03% 
to increase eyelash growth was assessed in a multicenter, 
double-masked, randomized, vehicle-controlled, pivotal 
trial.7,46 A more detailed presentation of the safety and 
efficacy results from the bimatoprost for eyelash growth 
pivotal trial is pending. Briefly, the clinical trial enrolled 
278 adults who had clinician-rated “minimal” or “moderate” 
eyelash prominence. Participants were randomized to receive 
treatment with bimatoprost ophthalmic solution 0.03% 
(n = 137) or vehicle (n = 141) once daily for four months. The 
primary efficacy measure was the clinician-rated four-point 
Global Eyelash Assessment (GEA) scale. The GEA scale, 
a proven, reliable, and reproducible instrument, asks raters 
to evaluate a patient’s overall upper eyelash prominence, 
focusing on the qualities of length, fullness, and darkness. 
The scale ranges from 1 (minimal) to 4 (very marked) and 
includes a photonumeric guide to assist raters.47 Response 
was defined as at least a 1-grade increase in GEA score.7,46 
Beginning at week 8 and continuing through the end of 
treatment (ie, week 16), statistically significant differences 
in the proportion of responders favoring bimatoprost oph-
thalmic solution 0.03% were observed (Figure 2).7 By week 
8, approximately half of all patients treated with bimatoprost 
ophthalmic solution 0.03% experienced at least a 1-grade 
increase in GEA score.
In addition to the clinician-rated GEA assessment of 
efficacy, changes in eyelash prominence were also evalu-
ated using digital image analysis with quantitative measures 
of eyelash length, fullness/thickness, and darkness.7,46 Clinical, Cosmetic and Investigational Dermatology 2010:3 43
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  Participants treated with bimatoprost ophthalmic solution 
0.03% demonstrated significantly greater improvements from 
baseline in these three variables beginning at week 8 and con-
tinuing through the end of the treatment (ie, week 16). At the 
end of the treatment, bimatoprost ophthalmic solution 0.03% 
was associated with more than a 12-fold greater increase in 
eyelash length than vehicle; a mean 1.4 mm increase was 
observed in the bimatoprost group versus 0.1 mm in the 
vehicle group.7 The percentage improvements in all three 
eyelash characteristics assessed by digital image analysis 
from baseline to week 16 were significantly greater in subjects 
treated with bimatoprost ophthalmic solution 0.03% than 
with the vehicle (Figure 3).7,46
Given the aesthetic aspects of treating hypotrichosis 
of the eyelashes, which can be highly personal and extend 
beyond objective measurements, the pivotal trial also included 
patient-reported outcomes (PROs) as measures of efficacy. 
Participants in the trial were asked to complete four question-
naires during the study including a validated 23-item primary 
questionnaire, completed at baseline and all postbaseline 
study visits.48 Comprising three domains, the PRO measure 
was designed to assess the patients’ static perception of 
the physical and subjective attributes of their eyelashes and 
eyelash care. The length, fullness, and overall satisfaction 
domain queried patients about their level of satisfaction with 
the physical attributes of their eyelashes. The confidence, 
attractiveness, and professionalism domain assessed satisfac-
tion with subjective attributes contingent on eyelash health. 
Daily routine collected data on patient perceptions of the time 
and effort required to make eyelashes presentable. At week 16, 
patients treated with bimatoprost ophthalmic solution 0.03% 
demonstrated significant improvements from baseline in all 
three domains (P  0.008) and all 23 items (P  0.05). On a 
single item that asked patients to rate their overall satisfaction 
with their eyelashes, approximately 65% of subjects treated 
with bimatoprost ophthalmic solution 0.03% reported that 
they were “satisfied” or “very satisfied” at week 16, improved 
from approximately 5% at baseline. Four weeks after com-
pleting treatment, study participants were asked to rate their 
change in overall satisfaction with the appearance of their 
eyes, daily activities, and quality of life. Significant differences 
(P  0.0001) favoring bimatoprost ophthalmic solution 0.03% 
were observed. For instance, 56% of subjects on bimatoprost 
treatment responded that their level of satisfaction was a “very 
great,” “great,” or “good” deal better than at the beginning 
of the study. Only 10% of patients receiving treatment with 
vehicle reported such levels of satisfaction.
The results of the pivotal trial indicate that bimatoprost 
ophthalmic solution 0.03% is an effective treatment for hypo-
trichosis of the eyelashes in healthy adults as measured by 
Subjects with at least a 1-grade increase
from baseline in Global Eyelash Assessment (%)
Bimatoprost ophthalmic solution 0.03% Vehicle
Week 1
Week 4
Week 8
Week 12
Week 16
0 20 40 60 80 100
a
a
a
Figure 2 Efficacy of bimatoprost ophthalmic solution 0.03% as assessed by Global Eyelash Assessment.7
aP  0.05 vs vehicle.Clinical, Cosmetic and Investigational Dermatology 2010:3 44
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clinician-assessed ratings, digital image analysis, and PROs.46 
While anecdotal in nature, in the author’s clinical practice, 
once-daily bimatoprost has also demonstrated effectiveness 
in increasing eyelash prominence, regularly leading to notice-
ably longer, thicker, and darker lashes (Figure 4). The use of 
bimatoprost ophthalmic solution 0.03% for eyelash growth 
is presently only indicated in adults with hypotrichosis. The 
ability of bimatoprost ophthalmic solution 0.03% to influence 
eyelash growth in patients with eyelash loss (eg, secondary 
to trauma, radiation, or alopecia areata) has not been fully 
evaluated, although evidence suggests that some patients with 
alopecia of the eyelashes may benefit from treatment with 
bimatoprost ophthalmic solution 0.03%.49,50
Safety of bimatoprost ophthalmic 
solution 0.03% for hypotrichosis
Evaluation of the safety of bimatoprost can draw from 
two data sets: the safety of ocularly instilled bimatoprost 
  ophthalmic solution 0.03% for the treatment of ocular 
hypertension and the safety of dermally applied bimatoprost 
ophthalmic solution 0.03% for hypotrichosis of the eye-
lashes. Since it has a long history as a glaucoma treatment, 
safety data for bimatoprost ophthalmic solution 0.03% as an 
eyedrop are understandably more extensive than for dermal 
administration. As an eyedrop for the treatment of ocular 
hypertension, bimatoprost ophthalmic solution 0.03% has 
been evaluated in trials lasting up to four years. Over the 
course of a four-year, double-masked, randomized trial 
comparing bimatoprost ophthalmic solution 0.03% with 
timolol, eyelash growth was reported by 60.3% of patients 
receiving bimatoprost once daily.24 Other common adverse 
events related to treatment with bimatoprost ophthalmic solu-
tion 0.03% included conjunctival hyperemia (50.0%), ocular 
burning (11.5%), foreign body sensation (11.5%), cataract 
(10.3%), eye dryness (7.7%), and eye pruritus (6.4%). In 
clinical trials, bimatoprost ophthalmic solution 0.03% (as an 
eyedrop) was associated with pigmentation of the periocular 
skin in approximately 3% to 10% of patients.19
The safety profile of bimatoprost ophthalmic solution 
0.03% appears considerably more favorable when applied 
dermally (for hypotrichosis of the eyelashes) as opposed to 
being instilled into the eye (for glaucoma). Differences in the 
exposure of ocular tissues to bimatoprost ophthalmic solution 
0.03% may explain such observations. In the four-month 
pivotal trial assessing bimatoprost ophthalmic solution 0.03% 
for eyelash growth, the most common adverse events were 
eye pruritus, conjunctival hyperemia, skin hyperpigmenta-
tion, ocular irritation, dry eye symptoms, and erythema of 
the eyelid. All adverse events occurred in less than 4% of 
subjects receiving bimatoprost ophthalmic solution 0.03%, 
Mean improvement from baseline at week 16 as
assessed by digital image analysis (% increase)
Bimatoprost ophthalmic solution 0.03% Vehicle
Length
Fullness
Darkness
0 20 40 60 80 100 120
a
a
a
Figure 3 Efficacy of bimatoprost ophthalmic solution 0.03% as assessed by digital image analysis.7
aP  0.05 vs vehicle.Clinical, Cosmetic and Investigational Dermatology 2010:3 45
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and only conjunctival hyperemia was significantly more 
common among subjects treated with bimatoprost ophthalmic 
solution 0.03% than with vehicle.7,46 Now that bimatoprost 
ophthalmic solution 0.03% is commercially available, larger 
real-life experiences with patients seems to parallel these 
potential “side effects” and has not been a significant cause of 
patient discontinuation of treatment. The incidence of these 
adverse events is also considerably higher when bimatoprost 
ophthalmic solution 0.03% is used as an eyedrop for a com-
parable length of therapy. For instance, in a three-month trial 
of once-daily treatment with bimatoprost ophthalmic solution 
0.03% for glaucoma or ocular hypertension, conjunctival 
hyperemia, and eye pruritus were reported by 46% and 9% 
of patients receiving the drug, respectively.25
As an ocular antihypertensive, the incidence of increased 
iris pigmentation, which is believed to be a permanent 
change,51 associated with once-daily bimatoprost is estimated 
to be 1.5%, with all recorded events occurring within the first 
year of treatment.24,28 Although this has been a significant 
focus of concern promulgated by the lay press and by many 
with little experience, no such events were observed in the 
clinical trial of bimatoprost ophthalmic solution 0.03% for 
eyelash growth.7,46 Additionally, whereas bimatoprost oph-
thalmic solution 0.03% instilled into the eye of patients with 
glaucoma significantly lowers IOP (its intended therapeutic 
effect), no clinically relevant changes in IOP were associated 
with dermal application of bimatoprost in healthy adults.7,46 
While statistically significant, the mean IOP differences 
between the bimatoprost- and vehicle-treated cohorts during 
the treatment period were less than 1 mmHg.46 The mean 
range of IOPs (difference of maximum and minimum IOP) 
during the study (baseline to week 16) was 3.7 mmHg among 
vehicle-treated subjects and 3.9 mmHg among bimatoprost-
treated subjects. For perspective, normal variation in IOP over 
a 24-hour period among healthy subjects is approximately 7 
mmHg.52
Several factors may contribute to the improved safety pro-
file observed when bimatoprost ophthalmic solution 0.03% is 
applied dermally. Skin hyperpigmentation, an adverse event 
reversible upon discontinuation of bimatoprost,6,31,33 appears to 
Figure 4 Sample images of patient eyelashes before and after 12 weeks of once-daily treatment with bimatoprost.
Notes: Photos courtesy of Steven Fagien, MD.
Baseline Bimatoprost-treated (12 weeks)Clinical, Cosmetic and Investigational Dermatology 2010:3 46
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be the result of drop-skin contact.53 The risk of such pigmentary 
changes can be minimized by reducing contact of the medica-
tion with the skin.53 Detailed instruction on safe and effective 
use has become commonplace in practitioner’s offices that 
prescribe and/or dispense bimatoprost ophthalmic solution 
0.03% and the proper application for eyelash growth using the 
supplied applicators would seemingly minimize the chance 
of unintended skin-bimatoprost contact. As demonstrated in 
an ocular splash test conducted using lissamine green dye, 
dermal application of bimatoprost ophthalmic solution 0.03% 
appears to deliver less medication to the ocular tissues than a 
drop instilled into the eye (Figure 5, data on file; Allergan, Inc.). 
Additional testing has demonstrated that, based on weight, 
approximately 5% of the dose of bimatoprost ophthalmic 
solution 0.03% on the applicator (ie, one drop) is delivered to 
the patient (data on file; Allergan, Inc.). Exposure of the ocular 
tissues to dermally applied bimatoprost ophthalmic solution 
0.03% may be further decreased as a result of the skin’s barrier 
function (data on file; Allergan, Inc.). Although evidence has 
demonstrated that exposure to bimatoprost ophthalmic solution 
0.03% is reduced when applied dermally compared with its use 
as an eyedrop, the long-term safety of bimatoprost for eyelash 
growth has not yet been specifically evaluated in clinical trials, 
although such a trial is underway.54 Additionally, as the safety 
of bimatoprost ophthalmic solution 0.03% for the treatment 
of hypotrichosis of the eyelashes has only been evaluated in 
healthy adults, clinicians are urged to use caution when treat-
ing patients receiving concomitant treatment for elevated IOP, 
as well as those with intraocular inflammation, risk factors for 
macular edema, or aphakia.7
Role in clinical practice
Given the importance of the appearance of the eye region, 
and specifically the eyelashes, in influencing perceptions of 
beauty, it is understandable that many options to help women 
increase the prominence of their eyelashes have been devel-
oped. Only bimatoprost ophthalmic solution 0.03%, however, 
is FDA-approved for the treatment of hypotrichosis of the 
eyelashes with proven efficacy and effectiveness. It clearly 
induced increased eyelash growth including improvements 
in length, thickness, and fullness in a controlled clinical 
trial. These improvements were demonstrated by objective 
and clinician-rated assessments as well as by participants’ 
satisfaction with both physical and subjective attributes of 
their eyelashes.
While the mechanisms of action of bimatoprost ophthal-
mic solution 0.03% have not been fully elucidated, it appears 
to stimulate eyelash follicles to enter and remain in anagen, 
resulting in increased eyelash length. Augmented melano-
genesis seems to be responsible for the increased darkness 
Figure 5 Example of dermal application of a tracer dye to mimic bimatoprost ophthalmic solution 0.03% to the upper eyelid margin using applicators results in the admin-
istration of a decreased dose compared with application as an eyedrop (Data on file;   Allergan, Inc.). The above image was taken following administration of one drop (ie, 
28–30 µL) of lissamine green as an eyedrop (right eye [top left, bottom left]) and one drop of lissamine green transferred to a sterile brush and applied to the dermal margin 
of the upper eyelid (left eye [top right, bottom right]).Clinical, Cosmetic and Investigational Dermatology 2010:3 47
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of eyelashes associated with treatment, while changes in the 
developing hair bulb are thought to result in thicker/fuller 
eyelashes.
Bimatoprost ophthalmic solution 0.03% offers patients 
a novel method of increasing the prominence of their eye-
lashes. While the effects of treatment are not immediate 
(as with artificial eyelashes or mascara), improvements in 
eyelash prominence can often be observed several weeks 
after initiating therapy, with most patients demonstrating 
appreciable improvements by week 8.7,46 Importantly, these 
improvements appear to be sustained throughout the duration 
of treatment. Patients should be advised that such changes 
are not permanent, but instead, are believed to subside after 
discontinuation of treatment.7 The safety and tolerability of 
bimatoprost ophthalmic solution 0.03% for eyelash growth 
is crucial in helping to define its role in clinical practice as 
an aesthetic treatment. It is reassuring that the safety profile 
of bimatoprost ophthalmic solution 0.03% applied dermally 
appears even more favorable than bimatoprost ophthalmic 
solution 0.03% instilled ocularly, a generally safe and well 
tolerated treatment for increased IOP with an extensively 
documented safety profile originating from multiple clinical 
trials and long-standing postmarketing experience. Decreased 
exposure of the ocular tissues to the active drug may account 
for the reduced incidences of adverse events observed with 
dermal administration. Although long-term trials are needed, 
iridial pigmentation has not been observed in patients using 
bimatoprost ophthalmic solution 0.03% during the clinical 
trial for hypotrichosis of the eyelashes. Other mild adverse 
events such as conjunctival hyperemia and ocular irritation 
or pruritus (presumed to be a prostaglandin effect) in many 
seem to be self-limited and symptoms can actually improve 
with continuation of treatment. In both the registration trial 
and in clinical practice, these mild effects are a rare cause 
for discontinuation of therapy after patients have perceived 
their aesthetic improvement of lash prominence.
Finally, although only FDA-approved for application to 
the upper eyelid lashes, future studies might include the use of 
bimatoprost ophthalmic solution 0.03% for other applications 
including the potential for the treatment of hypotrichosis of 
the lower eyelid, eyebrow, and scalp. The use of this agent for 
the treatment of chemotherapy-induced eyelash hypotrichosis 
is also presently under investigation.55
Also still under speculation and yet another topic of future 
investigation is what alterations of the approved treatment 
schedule would still constitute effective treatment from the 
start or as maintenance once the eyelash prominence has 
reached a satisfactory endpoint.
Conclusion
Taken together, the available data presented herein, growing 
postapproval clinical experiences, and exciting future applica-
tions suggest that bimatoprost ophthalmic solution 0.03% is 
an effective and safe treatment in a host of applications and 
another therapy that appears to improve the quality of life 
for those patients seeking aesthetic improvement of eyelash 
growth and prominence.
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